Pharmacokinetic study of acid in multiple sclerosis: Comparing mice and human pharmacokinetic parameters

Vijayshree Yadav, Gail Marracci, Myrna Y. Munar, Ganesh Cherala, Lauren E. Stuber, Lilia Alvarez, Lynne Shinto, Dennis Koop, Dennis Bourdette

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Lipoic acid is a natural anti-oxidant available as an oral supplement from a number of different manufacturers. Lipoic acid administered subcutaneously is an effective therapy for murine experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The aim of this study was to compare serum lipoic acid levels with oral dosing in patients with multiple sclerosis with serum levels in mice receiving subcutaneous doses of lipoic acid. We performed serum pharmacokinetic studies in patients with multiple sclerosis after a single oral dose of 1200mg lipoic acid. Patients received one of the three different racemic formulations randomly: tablet (Formulation A) and capsules (Formulations B and C). Mice pharmacokinetic studies were performed with three different subcutaneous doses (20, 50 and 100 mg/kg racemic lipoic acid). The pharmacokinetic parameters included Maximum Serum Concentrations (C max in μg/ml) and area under the curve0-infinity (AUC0-infinity in ng*min/ml). We found mean C max and AUC0-infinity in patients with multiple sclerosis as follows: group A (N = 7) 3.8 ± 2.6 and 443.1 ± 283.9; group B (N = 8) 9.9 ± 4.5 and 745.2 ± 308.7 and group C (N = 8) 10.3 ± 3.8 and 848.8 ± 360.5, respectively. Mean Cmax and AUC0-infinity in the mice were: 100 mg/kg lipoic acid: 30.9 ± 2.9 and 998 ± 245; 50 mg/kg lipoic acid: 7.6 ± 1.4 and 223 ± 20; 20 mg/kg lipoic acid: 2.7 ± 0.7 and 119 ± 33. We conclude that patients taking 1200 mg of lipoic acid from two of the three oral formulations achieved serum Cmax and AUC levels comparable to that observed in mice receiving 50 mg/kg subcutaneous dose of lipoic acid, which is a highly therapeutic dose in experimental autoimmune encephalomyelitis. A dose of 1200mg oral lipoic acid can achieve therapeutic serum levels in patients with multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)387-397
Number of pages11
JournalMultiple Sclerosis
Volume16
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Thioctic Acid
Multiple Sclerosis
Pharmacokinetics
Acids
Serum
Autoimmune Experimental Encephalomyelitis
Oxidants
Tablets
Area Under Curve
Capsules
Therapeutics

Keywords

  • Anti-oxidants
  • Dietary supplements
  • Experimental autoimmune encephalomyelitis
  • Lipoic acid
  • Multiple sclerosis
  • Pharmacokinetics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Pharmacokinetic study of acid in multiple sclerosis : Comparing mice and human pharmacokinetic parameters. / Yadav, Vijayshree; Marracci, Gail; Munar, Myrna Y.; Cherala, Ganesh; Stuber, Lauren E.; Alvarez, Lilia; Shinto, Lynne; Koop, Dennis; Bourdette, Dennis.

In: Multiple Sclerosis, Vol. 16, No. 4, 04.2010, p. 387-397.

Research output: Contribution to journalArticle

@article{556cf6319264442296451bd41297d3e8,
title = "Pharmacokinetic study of acid in multiple sclerosis: Comparing mice and human pharmacokinetic parameters",
abstract = "Lipoic acid is a natural anti-oxidant available as an oral supplement from a number of different manufacturers. Lipoic acid administered subcutaneously is an effective therapy for murine experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The aim of this study was to compare serum lipoic acid levels with oral dosing in patients with multiple sclerosis with serum levels in mice receiving subcutaneous doses of lipoic acid. We performed serum pharmacokinetic studies in patients with multiple sclerosis after a single oral dose of 1200mg lipoic acid. Patients received one of the three different racemic formulations randomly: tablet (Formulation A) and capsules (Formulations B and C). Mice pharmacokinetic studies were performed with three different subcutaneous doses (20, 50 and 100 mg/kg racemic lipoic acid). The pharmacokinetic parameters included Maximum Serum Concentrations (C max in μg/ml) and area under the curve0-infinity (AUC0-infinity in ng*min/ml). We found mean C max and AUC0-infinity in patients with multiple sclerosis as follows: group A (N = 7) 3.8 ± 2.6 and 443.1 ± 283.9; group B (N = 8) 9.9 ± 4.5 and 745.2 ± 308.7 and group C (N = 8) 10.3 ± 3.8 and 848.8 ± 360.5, respectively. Mean Cmax and AUC0-infinity in the mice were: 100 mg/kg lipoic acid: 30.9 ± 2.9 and 998 ± 245; 50 mg/kg lipoic acid: 7.6 ± 1.4 and 223 ± 20; 20 mg/kg lipoic acid: 2.7 ± 0.7 and 119 ± 33. We conclude that patients taking 1200 mg of lipoic acid from two of the three oral formulations achieved serum Cmax and AUC levels comparable to that observed in mice receiving 50 mg/kg subcutaneous dose of lipoic acid, which is a highly therapeutic dose in experimental autoimmune encephalomyelitis. A dose of 1200mg oral lipoic acid can achieve therapeutic serum levels in patients with multiple sclerosis.",
keywords = "Anti-oxidants, Dietary supplements, Experimental autoimmune encephalomyelitis, Lipoic acid, Multiple sclerosis, Pharmacokinetics",
author = "Vijayshree Yadav and Gail Marracci and Munar, {Myrna Y.} and Ganesh Cherala and Stuber, {Lauren E.} and Lilia Alvarez and Lynne Shinto and Dennis Koop and Dennis Bourdette",
year = "2010",
month = "4",
doi = "10.1177/1352458509359722",
language = "English (US)",
volume = "16",
pages = "387--397",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetic study of acid in multiple sclerosis

T2 - Comparing mice and human pharmacokinetic parameters

AU - Yadav, Vijayshree

AU - Marracci, Gail

AU - Munar, Myrna Y.

AU - Cherala, Ganesh

AU - Stuber, Lauren E.

AU - Alvarez, Lilia

AU - Shinto, Lynne

AU - Koop, Dennis

AU - Bourdette, Dennis

PY - 2010/4

Y1 - 2010/4

N2 - Lipoic acid is a natural anti-oxidant available as an oral supplement from a number of different manufacturers. Lipoic acid administered subcutaneously is an effective therapy for murine experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The aim of this study was to compare serum lipoic acid levels with oral dosing in patients with multiple sclerosis with serum levels in mice receiving subcutaneous doses of lipoic acid. We performed serum pharmacokinetic studies in patients with multiple sclerosis after a single oral dose of 1200mg lipoic acid. Patients received one of the three different racemic formulations randomly: tablet (Formulation A) and capsules (Formulations B and C). Mice pharmacokinetic studies were performed with three different subcutaneous doses (20, 50 and 100 mg/kg racemic lipoic acid). The pharmacokinetic parameters included Maximum Serum Concentrations (C max in μg/ml) and area under the curve0-infinity (AUC0-infinity in ng*min/ml). We found mean C max and AUC0-infinity in patients with multiple sclerosis as follows: group A (N = 7) 3.8 ± 2.6 and 443.1 ± 283.9; group B (N = 8) 9.9 ± 4.5 and 745.2 ± 308.7 and group C (N = 8) 10.3 ± 3.8 and 848.8 ± 360.5, respectively. Mean Cmax and AUC0-infinity in the mice were: 100 mg/kg lipoic acid: 30.9 ± 2.9 and 998 ± 245; 50 mg/kg lipoic acid: 7.6 ± 1.4 and 223 ± 20; 20 mg/kg lipoic acid: 2.7 ± 0.7 and 119 ± 33. We conclude that patients taking 1200 mg of lipoic acid from two of the three oral formulations achieved serum Cmax and AUC levels comparable to that observed in mice receiving 50 mg/kg subcutaneous dose of lipoic acid, which is a highly therapeutic dose in experimental autoimmune encephalomyelitis. A dose of 1200mg oral lipoic acid can achieve therapeutic serum levels in patients with multiple sclerosis.

AB - Lipoic acid is a natural anti-oxidant available as an oral supplement from a number of different manufacturers. Lipoic acid administered subcutaneously is an effective therapy for murine experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The aim of this study was to compare serum lipoic acid levels with oral dosing in patients with multiple sclerosis with serum levels in mice receiving subcutaneous doses of lipoic acid. We performed serum pharmacokinetic studies in patients with multiple sclerosis after a single oral dose of 1200mg lipoic acid. Patients received one of the three different racemic formulations randomly: tablet (Formulation A) and capsules (Formulations B and C). Mice pharmacokinetic studies were performed with three different subcutaneous doses (20, 50 and 100 mg/kg racemic lipoic acid). The pharmacokinetic parameters included Maximum Serum Concentrations (C max in μg/ml) and area under the curve0-infinity (AUC0-infinity in ng*min/ml). We found mean C max and AUC0-infinity in patients with multiple sclerosis as follows: group A (N = 7) 3.8 ± 2.6 and 443.1 ± 283.9; group B (N = 8) 9.9 ± 4.5 and 745.2 ± 308.7 and group C (N = 8) 10.3 ± 3.8 and 848.8 ± 360.5, respectively. Mean Cmax and AUC0-infinity in the mice were: 100 mg/kg lipoic acid: 30.9 ± 2.9 and 998 ± 245; 50 mg/kg lipoic acid: 7.6 ± 1.4 and 223 ± 20; 20 mg/kg lipoic acid: 2.7 ± 0.7 and 119 ± 33. We conclude that patients taking 1200 mg of lipoic acid from two of the three oral formulations achieved serum Cmax and AUC levels comparable to that observed in mice receiving 50 mg/kg subcutaneous dose of lipoic acid, which is a highly therapeutic dose in experimental autoimmune encephalomyelitis. A dose of 1200mg oral lipoic acid can achieve therapeutic serum levels in patients with multiple sclerosis.

KW - Anti-oxidants

KW - Dietary supplements

KW - Experimental autoimmune encephalomyelitis

KW - Lipoic acid

KW - Multiple sclerosis

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=77954683513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954683513&partnerID=8YFLogxK

U2 - 10.1177/1352458509359722

DO - 10.1177/1352458509359722

M3 - Article

C2 - 20150394

AN - SCOPUS:77954683513

VL - 16

SP - 387

EP - 397

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 4

ER -